Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: December 2007
-
The site for the Patent Resources Group (PRG) Advanced Courses this Spring is in Bonita Springs, FL. The usual courses will be offered, including: Chemical Patent Practice; Pharma & Biotech Strategies for Patent Prosecution, Hatch-Waxman, Litigation & Licensing; and a new course entitled FDA Orange Book and Listable Small Molecule Patent Practice. A number of…
-
By Donald Zuhn — On Monday, Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released a statement regarding the 2007 Performance and Accountability Report issued by the U.S. Patent and Trademark Office on November 15th (see "USPTO Announces "Record Breaking" 2007 Performance"). At the time of the report’s release, the Patent Office…
-
By Kevin E. Noonan — For the past several months, Genentech has been assailed by ophthalmologists and patients over its decision to ban compounding pharmacies from reformulating its anticancer drug Avastin® (bevacizumab, a monoclonal antibody) to be used for treating neovascular or "wet" age-related macular degeneration (AMD), a condition that if untreated leads…
-
By Christopher P. Singer — PDX Program In an e-Commerce alert notice sent by e-mail today, December 5, 2007, the USPTO provides a number of tips for completing a successful priority document exchange (PDX) request. Throughout the past year, the USPTO began exchanging priority documents electronically with the EPO and JPO through secure…
-
By Kevin E. Noonan — It is always surprising to non-scientists when they discover how little we know about the answers to some fundamental questions. Everyone knows, of course, the paradox that "we can land a man on the moon, but we can’t prevent the common cold." More esoterically, Dr. J.R. Powell at…
-
By Sherri Oslick — Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, and Watson Pharmaceuticals, Inc., have announced that they have reached a settlement agreement in Biovail’s lawsuit against Andrx Pharmaceuticals, Inc., a subsidiary of Watson. The lawsuit was filed following a paragraph IV certification as part of Andrx’s filing of an…
-
By Donald Zuhn — Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. announced today that the companies have entered into a merger agreement. Precision Therapeutics, Inc. is a privately-owned life sciences company based in Pittsburgh, PA that focuses on the development and commercialization of tests for use in individualizing cancer therapy. Oracle Healthcare…
-
By Kevin E. Noonan — Gene Quinn from the PLI blog reports today that Judge Cacheris has set the briefing schedule for summary judgment motions in the challenge to the claims and continuation rules enjoined by the Court on October 31st (see Patent Docs report). All parties must file summary judgment motions and…
-
By Donald Zuhn — Last Friday, Vaccinex, Inc. announced that it had been granted European Patent No. 1 340 088. According to the statement released by Vaccinex, the ‘088 patent covers the Rochester, New York-based company’s ActivMAb® antibody discovery technology platform, which can be used for the discovery and development of new monoclonal…
-
By Kevin E. Noonan — Breda Lund, writing in the November 28th edition of The Generic Line, reports that the Senate may consider its version of the patent "reform" bill, S. 1145, during the next session of the 110th Congress when it convenes next January. According to Ms. Lund, Matthew Sandgren, counsel to…
Patent Docs 